

IFW



Docket No.: A0345.0022
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Heinz Fretz et al.

Application No.: 10/562,623

Confirmation No.: 4155

Filed: December 23, 2005

Art Unit: Not Yet Assigned

For: PYRAZOLIDINEDIONE DERIVATIVES
AND THEIR USE AS PLATELET
AGGREGATION INHIBITORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

- ☒ This IDS is being filed before the First Office Action¹.
- ☐ This IDS is being filed after the issuance of the First Office Action but before the issuance of a Final Office Action².

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

- ☐ This IDS is being filed after the issuance of a Final Office Action, Ex Parte Quayle Action or Notice of Allowance but before the payment of the Issue Fee³.

Certifications:

If checked, the undersigned makes the following statement(s):

- ☐ Statement under 37 CFR § 1.97(e):

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

- ☐ Statement Under 37 C.F.R. § 1.704(d):

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application less than thirty days prior to the filing of this information disclosure statement.

Fee Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):

- ☐ If checked, the fee of \$180.00 set forth in 37 C.F.R. §1.17(p) is attached.

² The IDS *must* include *either* a certification under 37 C.F.R. §1.97(e) *or* the fee set forth in 37 C.F.R. §1.17(p).

³ The IDS *must* include *both* a certification under 37 C.F.R. §1.97(e) *and* the fee set forth in 37 C.F.R. §1.17(p).

Copies of Information:

In accordance with 37 C.F.R. §1.98(a), the following are enclosed:

- ☒ A legible copy⁴ of each document (or relevant portion thereof) cited in the attached PTO/SB/08, except for U.S. patent and U.S. published applications.
- ☒ With respect to any information which is not in English, a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, is attached. This concise explanation is provided by way of:
 - ☐ A translation of the relevant portions of the non-English language information⁵;
 - ☐ A statement explaining the relevant portions of the non-English language information;
 - ☐ A copy [and, where not in the English language, a translation] of at least the relevant portion(s)⁶ of the communication from a foreign patent office in a counterpart foreign application in which the information was cited; or
 - ☒ This information is contained in the specification of the present application.

⁴ A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) – (c). This exception does not apply to information cited in an International Application.

⁵ 37 C.F.R. §1.98(a)(3)(ii) *requires* that an English language translation be provided when a translation of the document, or portion thereof, “is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c).”

⁶ The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an “X”, “Y”, or “A” indication on a search report. MPEP §609 III A(3).

☐ In accordance with 37 C.F.R. 1.98(d), copies of the cited documents are not enclosed as they were provided in application Serial No. _____, filed _____, which the present application relies upon for an earlier effective filing date under 35 U.S.C. 120.

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: April 3, 2007

Respectfully submitted,

By 
Charles E. Miller
Registration No.: 24,576
DICKSTEIN SHAPIRO LLP
1177 Avenue of the Americas
41st Floor
New York, New York 10036-2714
(212) 277-6500
Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/562,623-Conf. #4155
				Filing Date	December 23, 2005
				First Named Inventor	Heinz Fretz
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	A0345.0022

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	-WO 00/54771	09-21-2000			
	BB	-WO 01/36438 A1	05-25-2001			
	BC	-WO 01/85722 A1	11-15-2001			
	BD	-WO 02/16381 A2	02-28-2002			
	BE	-WO 03/011872 A1	02-13-2003			
	BF	-WO 02/098856 A2	12-12-2002			
	BG	-WO 99/36425	07-22-1999			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Hareau et al., J. Am. Chem. Soc., Vol. 121, pgs. 3640-3650 (1999)	
	CB	The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators, Circulation, Vol. 90, pgs. 1631-1637 (1994)	
	CC	Gachet et al., British Journal of Haematology, Vol. 91, pgs. 434-444 (1995)	
	CD	Christian Gachet, "ADP Receptors of Platelets and their Inhibition", Thromb. Haemost., Vol. 86, pgs. 222-232 (2001)	
	CE	Fritsch et al., Arch. Pharm. (Weinheim), Vol. 319, pgs. 70-78 (1986)	
	CF	Dogne et al., Current Medicinal Chemistry, Vol. 9, pgs. 577-589 (2002)	
	CG	Doggrell et al., Drugs of the Future, Vol. 26, No. 9, pgs. 835-840 (2001)	
	CH	Conrad et al., Ber., pgs. 2282-2288 (1906)	
	CI	Carreno et al., J. Org. Chem., Vol. 60, pgs. 5328-5331 (1995)	
	CJ	CAPRIE Steering Committee, "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE", The Lancet, Vol. 348, pgs. 1329-1339 (1996)	
	CK	Born et al., J. Physiol., Vol. 168, pgs. 178-195 (1963)	
	CL	Berge et al., Journal of Pharmaceutical Sciences, Vol. 66, pgs. 1-19 (1977)	
	CM	Batsanov et al., J. Chem. Soc. Perkin Trans. 1, pgs. 1281-1294 (1995)	
	CN	Barnard et al., TRENDS in Pharmacological Sciences, Vol. 22, pgs. 388-391 (2001)	
	CO	Elliott M. Antman, M.D., "Hirudin in Acute Myocardial Infarction", Circulation, Vol. 90, pgs. 1624-1630 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/562,623-Conf. #4155
				Filing Date	December 23, 2005
				First Named Inventor	Heinz Fretz
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	A0345.0022

CP	Kam et al, Anaesthesia, Vol. 58, pgs. 28-35 (2003)	
CQ	Mann et al., J. Chem. Soc., ps. 3830-3834 (1959)	
CR	Michaelis et al., Ber., pgs. 1502-1513 (1892)	
CS	Michaelis et al., Ber., pgs. 3568-3569 (1907)	
CT	Neuhaus, M.D. et al., Circulation, Vol. 90, pgs. 1638-1642 (1994)	
CU	Nielsen et al., J. Med. Chem., Vol. 41, pgs. 4819-4832 (1998)	
CV	Offermans et al., Nature, Vol. 389, pgs. 183-186 (1997)	
CW	Ortuno et al., Tetrahedron, Vol. 43, pgs. 2191-2198 (1987)	
CX	Remijn et al., Arterioscler. Thromb. Vasc. Biol., Vol. 22, pgs. 686-691 (2002)	
CY	Sammy R. Shaver, "P2Y receptors: Biological advances and therapeutic opportunities", Current Opinion in Drug Discovery & Development, Vol. 4, No. 5, pgs. 665-670 (2001)	
CZ	Turner et al., Blood, Vol. 98, pgs. 3340-3345 (2001)	
CA1	Wong, M.D. et al., "Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention", JAMA, Vol. 289, No. 3, pgs. 331-342 (2003)	
CB1	Weissberger et al., J. Am. Chem. Soc., Vol. 65, pgs. 52-54 (1943)	
CC1	J. Van Alphen, Recl. Trav. Chim. Pays-Bas, pgs. 823-866 (1924)	
CD1	The EPIC Investigators, "Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty, Vol. 330, pgs. 956-961 (1994)	
CE1	Trost et al., J. Org. Chem., Vol. 48, pgs. 3346-3347 (1983)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--